8-[(2R,6S)-2,6-dimethylmorpholin-4-yl]octylcarbamic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 8-[(2R,6S)-2,6-dimethylmorpholin-4-yl]octylcarbamic acid
• 化学式: C₁₅H₃₀N₂O₃
• 分子量: 286.41
• InChiKey: VJHKDLAVMMBCDF-OKILXGFUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  20
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  61.8
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Combinations
  申请人：Field John Mark

  公开号：US20050065176A1

  公开（公告）日：2005-03-24

  The instant invention relates to a combination of an alpha-2-delta ligand and an AChE inhibitor for use in therapy, particularly in the treatment of pain, particularly neuropathic pain. Particularly preferred alpha-2-delta ligands are gabapentin and pregabalin. Particularly preferred ACHE inhibitors are donepezil (Aricept®), tacrine (cognex®), rivastigmine (Exelon®), physostgmine (Synapton®), galantamine (Reminyl), metrifonate (Promem), neostigmine (Prostigmin) and icopezil.

  该瞬时发明涉及一种α-2-δ配体和AChE抑制剂的组合，用于治疗，特别是用于治疗疼痛，特别是神经病性疼痛的治疗。特别偏爱的α-2-δ配体是加巴喷丁和普雷加巴林。特别偏爱的ACHE抑制剂包括多奈哌齐（阿力普特®）、他克林（可格林®）、利伐司特（埃克洛尔®）、生理毒素（斯纳普通®）、加兰他明（瑞莫灵）、美曲磷（普罗美）、新斯的明（普罗斯的明）和伊科唑。
• Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitors
  申请人：COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES

  公开号：US10765670B2

  公开（公告）日：2020-09-08

  This invention relates to improvements in therapeutic neurological and neuropsychic treatments using acetylcholinesterase inhibitors. More specifically, the invention enables the effects of the reversible acetylcholinesterase inhibitor donepezil to be potentiated by certain molecules, referred to here as connexin-blocking agents. Said connexin-blocking agent is preferably meclofenamic acid.

  本发明涉及使用乙酰胆碱酯酶抑制剂对神经和神经心理治疗的改进。更具体地说，本发明使可逆性乙酰胆碱酯酶抑制剂多奈哌齐的作用能够通过某些分子（在此称为连接蛋白阻断剂）得到增强。所述附着素阻断剂最好是甲氯芬那酸。
• Methods and compositions for improving cognitive function
  申请人：AgeneBio, Inc.

  公开号：US11160785B2

  公开（公告）日：2021-11-02

  The invention relates to compositions comprising a synaptic vesicle glycoprotein 2A (SV2A) inhibitor in an extended release and an acetylcholinesterase inhibitor (AChEIs). The invention also relates to using such compositions in treating cognitive impairment associated with central nervous system disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), dementia, Alzheimer's Disease (AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease (PD), autism, compulsive behavior, and substance addiction.

  本发明涉及一种组合物，该组合物包含一种缓释的突触小泡糖蛋白 2A (SV2A) 抑制剂和一种乙酰胆碱酯酶抑制剂 (AChEIs)。本发明还涉及使用此类组合物治疗有需要或有风险的受试者与中枢神经系统疾病相关的认知障碍，包括但不限于具有或有风险的受试者与年龄相关的认知障碍、轻度认知障碍（MCI）、痴呆症、阿尔茨海默氏症（Alzheimer）、老年痴呆症（Dementia）、阿尔茨海默氏症（Alzheimer）等、痴呆症、阿尔茨海默病 (AD)、前驱 AD、创伤后应激障碍 (PTSD)、精神分裂症、双相情感障碍、肌萎缩性脊髓侧索硬化症 (ALS)、癌症治疗相关认知障碍、智力迟钝、帕金森病 (PD)、自闭症、强迫行为和药物成瘾。
• COMBINATIONS OF ALPHA-2-DELTA LIGANDS AND ACETYLCHOLINESTERASE INHIBITORS
  申请人：Pfizer Limited

  公开号：EP1667722A1

  公开（公告）日：2006-06-14
• METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
  申请人：The Johns Hopkins University

  公开号：EP2533645A1

  公开（公告）日：2012-12-19